| 1 | groups | 145,076 |
| 2 | backpacks | 14 |
| 3 | groups-group | 6 |
| 4 | progressives | 6 |
| 5 | windrows | 5 |
| 6 | isocentres | 4 |
| 7 | actins | 3 |
| 8 | daycares | 3 |
| 9 | ghsgts | 3 |
| 10 | subtrials | 3 |
| 11 | test-days | 3 |
| 12 | test-meals | 3 |
| 13 | treatment-groups | 3 |
| 14 | tsvs | 3 |
| 15 | 3,5-bis- | 2 |
| 16 | antihistamine-analgesic | 2 |
| 17 | aproaches | 2 |
| 18 | capnometers | 2 |
| 19 | citases | 2 |
| 20 | clkt | 2 |
| 21 | edifices | 2 |
| 22 | egas | 2 |
| 23 | groups/interviews | 2 |
| 24 | heat-presses | 2 |
| 25 | mediets | 2 |
| 26 | meta-attributes | 2 |
| 27 | monoglucuronides | 2 |
| 28 | noncancers | 2 |
| 29 | pdtp-dfbt | 2 |
| 30 | pumpings | 2 |
| 31 | sirluc | 2 |
| 32 | study-groups | 2 |
| 33 | sub-families | 2 |
| 34 | subphyla | 2 |
| 35 | tablets/wk | 2 |
| 36 | tetra-hydro-furan | 2 |
| 37 | twogroups | 2 |
| 38 | uran-yl | 2 |
| 39 | ≤30years | 2 |
| 40 | 0.052°c | 1 |
| 41 | 0.22-0.58 | 1 |
| 42 | 0000h-1200h | 1 |
| 43 | 03/01/2009-03/31/2012 | 1 |
| 44 | 1-1/bpvr | 1 |
| 45 | 1.1.-30.9.2009 | 1 |
| 46 | 1.25×10 | 1 |
| 47 | 1/6-1/3 | 1 |
| 48 | 10816-5 | 1 |
| 49 | 11731-2 | 1 |
| 50 | 123i-iodobenzamide | 1 |
| 51 | 13w | 1 |
| 52 | 15.9±0.8 | 1 |
| 53 | 15μgl | 1 |
| 54 | 18/year | 1 |
| 55 | 19-625µg/ml | 1 |
| 56 | 190-200gm | 1 |
| 57 | 1925-1934 | 1 |
| 58 | 1949-1991 | 1 |
| 59 | 1958-1990 | 1 |
| 60 | 1964-68 | 1 |
| 61 | 1971-1972 | 1 |
| 62 | 1972-1975 | 1 |
| 63 | 1975-1988 | 1 |
| 64 | 1975-88 | 1 |
| 65 | 1989-99 | 1 |
| 66 | 1:1-1:2 | 1 |
| 67 | 2,2,6,6-tetrametil-3,5-heptanodione | 1 |
| 68 | 2,3-aminopyridine | 1 |
| 69 | 2-ethyl-1- | 1 |
| 70 | 2-tert-but-oxy-6-fluoro-3- | 1 |
| 71 | 2.98-13.37 | 1 |
| 72 | 20-30°c | 1 |
| 73 | 20-87microm | 1 |
| 74 | 2010-2030 | 1 |
| 75 | 24-h-prompted | 1 |
| 76 | 25.5±5.2years | 1 |
| 77 | 2p.m | 1 |
| 78 | 3,3'-dihydroxyflavone | 1 |
| 79 | 3-9.2 | 1 |
| 80 | 3-spiro-2'-pyrrolidine-3'-spiro-3″-piperidine-2,3″-dione | 1 |
| 81 | 30-104 | 1 |
| 82 | 35.9+/-13.0 | 1 |
| 83 | 36.63-39.65°c | 1 |
| 84 | 39-2500µg/ml | 1 |
| 85 | 39-h | 1 |
| 86 | 4,4'-difluoro-8- | 1 |
| 87 | 40-100×10 | 1 |
| 88 | 40.14×10 | 1 |
| 89 | 44.8yrs | 1 |
| 90 | 49y | 1 |
| 91 | 55+y | 1 |
| 92 | 55.9± | 1 |
| 93 | 56.9+/-10.3 | 1 |
| 94 | 58.1+/-16.4 | 1 |
| 95 | 59,5 | 1 |
| 96 | 59.1yrs | 1 |
| 97 | 61years | 1 |
| 98 | 62.05±7.10 | 1 |
| 99 | 62.1±11.8 | 1 |
| 100 | 70.0years | 1 |
| 101 | 75-52°c | 1 |
| 102 | 79.2-158.8microg/ml | 1 |
| 103 | 7919-5 | 1 |
| 104 | 7·13 | 1 |
| 105 | 80–92 | 1 |
| 106 | 81/82 | 1 |
| 107 | 86·7 | 1 |
| 108 | 9+/-5 | 1 |
| 109 | 9917-1 | 1 |
| 110 | 9:00am-10:00am | 1 |
| 111 | acetyl-acetonate | 1 |
| 112 | ag-complexes | 1 |
| 113 | alu-elements | 1 |
| 114 | angioectasias | 1 |
| 115 | anti-slex | 1 |
| 116 | aotfs | 1 |
| 117 | aspartates | 1 |
| 118 | b-strains | 1 |
| 119 | b6129f2 | 1 |
| 120 | bisbenzimidazoles | 1 |
| 121 | bmi-groups | 1 |
| 122 | breast-feedings | 1 |
| 123 | c57bl/6jjcl | 1 |
| 124 | canine-laypeople | 1 |
| 125 | cantonments | 1 |
| 126 | cartridges/day | 1 |
| 127 | cbp-hbp | 1 |
| 128 | chirps | 1 |
| 129 | clausenamide | 1 |
| 130 | cocaine-opiate | 1 |
| 131 | color-temperatures | 1 |
| 132 | compounds-trans-phytol | 1 |
| 133 | courses-a | 1 |
| 134 | cpets | 1 |
| 135 | declensions | 1 |
| 136 | deltac3 | 1 |
| 137 | deltamcr | 1 |
| 138 | deltasorb | 1 |
| 139 | deltoid-intramuscular | 1 |
| 140 | dxa-results | 1 |
| 141 | ehv1/ehv4 | 1 |
| 142 | empirical-based | 1 |
| 143 | feeding-groups | 1 |
| 144 | ferredoxin-type | 1 |
| 145 | flavanol-c-glucosides | 1 |
| 146 | frontomaxillo-facial | 1 |
| 147 | full-duration | 1 |
| 148 | fy2002-fy2006 | 1 |
| 149 | gdt-parameters | 1 |
| 150 | gnathostomulids | 1 |
| 151 | groups-frs | 1 |
| 152 | groups.udca | 1 |
| 153 | grupos | 1 |
| 154 | h2-d | 1 |
| 155 | half-cysteines | 1 |
| 156 | haloperidol/amisulpride | 1 |
| 157 | high-polyunsaturated-fatty-acid | 1 |
| 158 | high-pressure/temperature | 1 |
| 159 | hirsutinolides | 1 |
| 160 | hp-np | 1 |
| 161 | htco | 1 |
| 162 | hydrophobic-aromatics | 1 |
| 163 | hydroxysterols | 1 |
| 164 | indoline-2-thione | 1 |
| 165 | inquests | 1 |
| 166 | intraocularly/intranasally | 1 |
| 167 | ionizations | 1 |
| 168 | isoflavans | 1 |
| 169 | isopimarane | 1 |
| 170 | lesion-to-ventricle | 1 |
| 171 | lignanamide | 1 |
| 172 | linoleic/oleic | 1 |
| 173 | lithotrities | 1 |
| 174 | loh/msi | 1 |
| 175 | malvidin-3-glucoside- | 1 |
| 176 | margin-pontic/connector | 1 |
| 177 | mdm2/p21 | 1 |
| 178 | metaregistries | 1 |
| 179 | methyl-2- | 1 |
| 180 | methyl-indole | 1 |
| 181 | mid-pubertal | 1 |
| 182 | midmyocardium/endocardium | 1 |
| 183 | midmyocardium/epicardium | 1 |
| 184 | mnhsc70s | 1 |
| 185 | monochromium | 1 |
| 186 | n-alkylimidazole | 1 |
| 187 | n-phenylglycine | 1 |
| 188 | navo | 1 |
| 189 | neuroticismxextraversion | 1 |
| 190 | non-chloracnegens | 1 |
| 191 | non-fusions | 1 |
| 192 | non-white-blood-cell | 1 |
| 193 | noncompressed | 1 |
| 194 | nontenderized | 1 |
| 195 | ob-folds | 1 |
| 196 | on-trade | 1 |
| 197 | overs | 1 |
| 198 | pain-types | 1 |
| 199 | pet-ct-positive | 1 |
| 200 | phosphodiestearase-5 | 1 |
| 201 | pianos | 1 |
| 202 | poly-pom-mofs | 1 |
| 203 | post-spect | 1 |
| 204 | pre-spect | 1 |
| 205 | preheat-treated | 1 |
| 206 | pt-ht | 1 |
| 207 | regimens-zidovudine-lamivudine-abacavir | 1 |
| 208 | regimens/schedules | 1 |
| 209 | retreats | 1 |
| 210 | sevoflurane/desflurane | 1 |
| 211 | strain-gauges | 1 |
| 212 | studies.meta-analysis | 1 |
| 213 | sub-protocols | 1 |
| 214 | subranges | 1 |
| 215 | t-junctions | 1 |
| 216 | task-sets | 1 |
| 217 | task-unspecific | 1 |
| 218 | tba-implanted | 1 |
| 219 | tc-monitors | 1 |
| 220 | tetra-cyano-ethyl-ene | 1 |
| 221 | tetrahydroxanthene-1,3 | 1 |
| 222 | tioblast™ | 1 |
| 223 | tmsv-16-sd | 1 |
| 224 | trans-1-amino-3-fluoro-1- | 1 |
| 225 | treatment-sessions | 1 |
| 226 | vass-users | 1 |
| 227 | weeks.results | 1 |
| 228 | weeks=arm | 1 |
| 229 | wheelers | 1 |
| 230 | x≤x | 1 |
| 231 | years.adenoidectomy | 1 |
| 232 | β-apo-8-carotenal | 1 |
| 233 | €20,807 | 1 |
| 234 | €23,231 | 1 |
| 235 | €31,241 | 1 |
| 236 | €4,519 | 1 |
| 237 | €7,600.00 | 1 |
| 238 | ⩾35 | 1 |
| 239 | ⩾55 | 1 |
| 1 | 0.052°c | 1 |
| 2 | 0.22-0.58 | 1 |
| 3 | 0000h-1200h | 1 |
| 4 | 03/01/2009-03/31/2012 | 1 |
| 5 | 1-1/bpvr | 1 |
| 6 | 1.1.-30.9.2009 | 1 |
| 7 | 1.25×10 | 1 |
| 8 | 1/6-1/3 | 1 |
| 9 | 10816-5 | 1 |
| 10 | 11731-2 | 1 |
| 11 | 123i-iodobenzamide | 1 |
| 12 | 13w | 1 |
| 13 | 15.9±0.8 | 1 |
| 14 | 15μgl | 1 |
| 15 | 18/year | 1 |
| 16 | 19-625µg/ml | 1 |
| 17 | 190-200gm | 1 |
| 18 | 1925-1934 | 1 |
| 19 | 1949-1991 | 1 |
| 20 | 1958-1990 | 1 |
| 21 | 1964-68 | 1 |
| 22 | 1971-1972 | 1 |
| 23 | 1972-1975 | 1 |
| 24 | 1975-1988 | 1 |
| 25 | 1975-88 | 1 |
| 26 | 1989-99 | 1 |
| 27 | 1:1-1:2 | 1 |
| 28 | 2,2,6,6-tetrametil-3,5-heptanodione | 1 |
| 29 | 2,3-aminopyridine | 1 |
| 30 | 2-ethyl-1- | 1 |
| 31 | 2-tert-but-oxy-6-fluoro-3- | 1 |
| 32 | 2.98-13.37 | 1 |
| 33 | 20-30°c | 1 |
| 34 | 20-87microm | 1 |
| 35 | 2010-2030 | 1 |
| 36 | 24-h-prompted | 1 |
| 37 | 25.5±5.2years | 1 |
| 38 | 2p.m | 1 |
| 39 | 3,3'-dihydroxyflavone | 1 |
| 40 | 3,5-bis- | 2 |
| 41 | 3-9.2 | 1 |
| 42 | 3-spiro-2'-pyrrolidine-3'-spiro-3″-piperidine-2,3″-dione | 1 |
| 43 | 30-104 | 1 |
| 44 | 35.9+/-13.0 | 1 |
| 45 | 36.63-39.65°c | 1 |
| 46 | 39-2500µg/ml | 1 |
| 47 | 39-h | 1 |
| 48 | 4,4'-difluoro-8- | 1 |
| 49 | 40-100×10 | 1 |
| 50 | 40.14×10 | 1 |
| 51 | 44.8yrs | 1 |
| 52 | 49y | 1 |
| 53 | 55+y | 1 |
| 54 | 55.9± | 1 |
| 55 | 56.9+/-10.3 | 1 |
| 56 | 58.1+/-16.4 | 1 |
| 57 | 59,5 | 1 |
| 58 | 59.1yrs | 1 |
| 59 | 61years | 1 |
| 60 | 62.05±7.10 | 1 |
| 61 | 62.1±11.8 | 1 |
| 62 | 70.0years | 1 |
| 63 | 75-52°c | 1 |
| 64 | 79.2-158.8microg/ml | 1 |
| 65 | 7919-5 | 1 |
| 66 | 7·13 | 1 |
| 67 | 80–92 | 1 |
| 68 | 81/82 | 1 |
| 69 | 86·7 | 1 |
| 70 | 9+/-5 | 1 |
| 71 | 9917-1 | 1 |
| 72 | 9:00am-10:00am | 1 |
| 73 | acetyl-acetonate | 1 |
| 74 | actins | 3 |
| 75 | ag-complexes | 1 |
| 76 | alu-elements | 1 |
| 77 | angioectasias | 1 |
| 78 | anti-slex | 1 |
| 79 | antihistamine-analgesic | 2 |
| 80 | aotfs | 1 |
| 81 | aproaches | 2 |
| 82 | aspartates | 1 |
| 83 | b-strains | 1 |
| 84 | b6129f2 | 1 |
| 85 | backpacks | 14 |
| 86 | bisbenzimidazoles | 1 |
| 87 | bmi-groups | 1 |
| 88 | breast-feedings | 1 |
| 89 | c57bl/6jjcl | 1 |
| 90 | canine-laypeople | 1 |
| 91 | cantonments | 1 |
| 92 | capnometers | 2 |
| 93 | cartridges/day | 1 |
| 94 | cbp-hbp | 1 |
| 95 | chirps | 1 |
| 96 | citases | 2 |
| 97 | clausenamide | 1 |
| 98 | clkt | 2 |
| 99 | cocaine-opiate | 1 |
| 100 | color-temperatures | 1 |
| 101 | compounds-trans-phytol | 1 |
| 102 | courses-a | 1 |
| 103 | cpets | 1 |
| 104 | daycares | 3 |
| 105 | declensions | 1 |
| 106 | deltac3 | 1 |
| 107 | deltamcr | 1 |
| 108 | deltasorb | 1 |
| 109 | deltoid-intramuscular | 1 |
| 110 | dxa-results | 1 |
| 111 | edifices | 2 |
| 112 | egas | 2 |
| 113 | ehv1/ehv4 | 1 |
| 114 | empirical-based | 1 |
| 115 | feeding-groups | 1 |
| 116 | ferredoxin-type | 1 |
| 117 | flavanol-c-glucosides | 1 |
| 118 | frontomaxillo-facial | 1 |
| 119 | full-duration | 1 |
| 120 | fy2002-fy2006 | 1 |
| 121 | gdt-parameters | 1 |
| 122 | ghsgts | 3 |
| 123 | gnathostomulids | 1 |
| 124 | groups | 145,076 |
| 125 | groups-frs | 1 |
| 126 | groups-group | 6 |
| 127 | groups.udca | 1 |
| 128 | groups/interviews | 2 |
| 129 | grupos | 1 |
| 130 | h2-d | 1 |
| 131 | half-cysteines | 1 |
| 132 | haloperidol/amisulpride | 1 |
| 133 | heat-presses | 2 |
| 134 | high-polyunsaturated-fatty-acid | 1 |
| 135 | high-pressure/temperature | 1 |
| 136 | hirsutinolides | 1 |
| 137 | hp-np | 1 |
| 138 | htco | 1 |
| 139 | hydrophobic-aromatics | 1 |
| 140 | hydroxysterols | 1 |
| 141 | indoline-2-thione | 1 |
| 142 | inquests | 1 |
| 143 | intraocularly/intranasally | 1 |
| 144 | ionizations | 1 |
| 145 | isocentres | 4 |
| 146 | isoflavans | 1 |
| 147 | isopimarane | 1 |
| 148 | lesion-to-ventricle | 1 |
| 149 | lignanamide | 1 |
| 150 | linoleic/oleic | 1 |
| 151 | lithotrities | 1 |
| 152 | loh/msi | 1 |
| 153 | malvidin-3-glucoside- | 1 |
| 154 | margin-pontic/connector | 1 |
| 155 | mdm2/p21 | 1 |
| 156 | mediets | 2 |
| 157 | meta-attributes | 2 |
| 158 | metaregistries | 1 |
| 159 | methyl-2- | 1 |
| 160 | methyl-indole | 1 |
| 161 | mid-pubertal | 1 |
| 162 | midmyocardium/endocardium | 1 |
| 163 | midmyocardium/epicardium | 1 |
| 164 | mnhsc70s | 1 |
| 165 | monochromium | 1 |
| 166 | monoglucuronides | 2 |
| 167 | n-alkylimidazole | 1 |
| 168 | n-phenylglycine | 1 |
| 169 | navo | 1 |
| 170 | neuroticismxextraversion | 1 |
| 171 | non-chloracnegens | 1 |
| 172 | non-fusions | 1 |
| 173 | non-white-blood-cell | 1 |
| 174 | noncancers | 2 |
| 175 | noncompressed | 1 |
| 176 | nontenderized | 1 |
| 177 | ob-folds | 1 |
| 178 | on-trade | 1 |
| 179 | overs | 1 |
| 180 | pain-types | 1 |
| 181 | pdtp-dfbt | 2 |
| 182 | pet-ct-positive | 1 |
| 183 | phosphodiestearase-5 | 1 |
| 184 | pianos | 1 |
| 185 | poly-pom-mofs | 1 |
| 186 | post-spect | 1 |
| 187 | pre-spect | 1 |
| 188 | preheat-treated | 1 |
| 189 | progressives | 6 |
| 190 | pt-ht | 1 |
| 191 | pumpings | 2 |
| 192 | regimens-zidovudine-lamivudine-abacavir | 1 |
| 193 | regimens/schedules | 1 |
| 194 | retreats | 1 |
| 195 | sevoflurane/desflurane | 1 |
| 196 | sirluc | 2 |
| 197 | strain-gauges | 1 |
| 198 | studies.meta-analysis | 1 |
| 199 | study-groups | 2 |
| 200 | sub-families | 2 |
| 201 | sub-protocols | 1 |
| 202 | subphyla | 2 |
| 203 | subranges | 1 |
| 204 | subtrials | 3 |
| 205 | t-junctions | 1 |
| 206 | tablets/wk | 2 |
| 207 | task-sets | 1 |
| 208 | task-unspecific | 1 |
| 209 | tba-implanted | 1 |
| 210 | tc-monitors | 1 |
| 211 | test-days | 3 |
| 212 | test-meals | 3 |
| 213 | tetra-cyano-ethyl-ene | 1 |
| 214 | tetra-hydro-furan | 2 |
| 215 | tetrahydroxanthene-1,3 | 1 |
| 216 | tioblast™ | 1 |
| 217 | tmsv-16-sd | 1 |
| 218 | trans-1-amino-3-fluoro-1- | 1 |
| 219 | treatment-groups | 3 |
| 220 | treatment-sessions | 1 |
| 221 | tsvs | 3 |
| 222 | twogroups | 2 |
| 223 | uran-yl | 2 |
| 224 | vass-users | 1 |
| 225 | weeks.results | 1 |
| 226 | weeks=arm | 1 |
| 227 | wheelers | 1 |
| 228 | windrows | 5 |
| 229 | x≤x | 1 |
| 230 | years.adenoidectomy | 1 |
| 231 | β-apo-8-carotenal | 1 |
| 232 | €20,807 | 1 |
| 233 | €23,231 | 1 |
| 234 | €31,241 | 1 |
| 235 | €4,519 | 1 |
| 236 | €7,600.00 | 1 |
| 237 | ≤30years | 2 |
| 238 | ⩾35 | 1 |
| 239 | ⩾55 | 1 |
| 1 | 2-ethyl-1- | 1 |
| 2 | trans-1-amino-3-fluoro-1- | 1 |
| 3 | methyl-2- | 1 |
| 4 | 2-tert-but-oxy-6-fluoro-3- | 1 |
| 5 | 4,4'-difluoro-8- | 1 |
| 6 | malvidin-3-glucoside- | 1 |
| 7 | 3,5-bis- | 2 |
| 8 | 35.9+/-13.0 | 1 |
| 9 | €7,600.00 | 1 |
| 10 | 62.05±7.10 | 1 |
| 11 | 40-100×10 | 1 |
| 12 | 40.14×10 | 1 |
| 13 | 1.25×10 | 1 |
| 14 | 2010-2030 | 1 |
| 15 | 1958-1990 | 1 |
| 16 | 9917-1 | 1 |
| 17 | mdm2/p21 | 1 |
| 18 | €23,231 | 1 |
| 19 | €31,241 | 1 |
| 20 | 1949-1991 | 1 |
| 21 | 11731-2 | 1 |
| 22 | 3-9.2 | 1 |
| 23 | 03/01/2009-03/31/2012 | 1 |
| 24 | 1971-1972 | 1 |
| 25 | 81/82 | 1 |
| 26 | 80–92 | 1 |
| 27 | 1:1-1:2 | 1 |
| 28 | b6129f2 | 1 |
| 29 | tetrahydroxanthene-1,3 | 1 |
| 30 | 56.9+/-10.3 | 1 |
| 31 | 1/6-1/3 | 1 |
| 32 | 7·13 | 1 |
| 33 | deltac3 | 1 |
| 34 | 58.1+/-16.4 | 1 |
| 35 | 30-104 | 1 |
| 36 | 1925-1934 | 1 |
| 37 | ehv1/ehv4 | 1 |
| 38 | 59,5 | 1 |
| 39 | 9+/-5 | 1 |
| 40 | 10816-5 | 1 |
| 41 | 7919-5 | 1 |
| 42 | phosphodiestearase-5 | 1 |
| 43 | ⩾35 | 1 |
| 44 | ⩾55 | 1 |
| 45 | 1972-1975 | 1 |
| 46 | fy2002-fy2006 | 1 |
| 47 | €20,807 | 1 |
| 48 | 2.98-13.37 | 1 |
| 49 | 86·7 | 1 |
| 50 | 15.9±0.8 | 1 |
| 51 | 62.1±11.8 | 1 |
| 52 | 0.22-0.58 | 1 |
| 53 | 1964-68 | 1 |
| 54 | 1975-88 | 1 |
| 55 | 1975-1988 | 1 |
| 56 | 1.1.-30.9.2009 | 1 |
| 57 | €4,519 | 1 |
| 58 | 1989-99 | 1 |
| 59 | courses-a | 1 |
| 60 | groups.udca | 1 |
| 61 | subphyla | 2 |
| 62 | deltasorb | 1 |
| 63 | linoleic/oleic | 1 |
| 64 | task-unspecific | 1 |
| 65 | antihistamine-analgesic | 2 |
| 66 | sirluc | 2 |
| 67 | 20-30°c | 1 |
| 68 | 75-52°c | 1 |
| 69 | 0.052°c | 1 |
| 70 | 36.63-39.65°c | 1 |
| 71 | h2-d | 1 |
| 72 | empirical-based | 1 |
| 73 | noncompressed | 1 |
| 74 | preheat-treated | 1 |
| 75 | tba-implanted | 1 |
| 76 | 24-h-prompted | 1 |
| 77 | nontenderized | 1 |
| 78 | high-polyunsaturated-fatty-acid | 1 |
| 79 | tmsv-16-sd | 1 |
| 80 | on-trade | 1 |
| 81 | lignanamide | 1 |
| 82 | clausenamide | 1 |
| 83 | 123i-iodobenzamide | 1 |
| 84 | haloperidol/amisulpride | 1 |
| 85 | lesion-to-ventricle | 1 |
| 86 | methyl-indole | 1 |
| 87 | n-alkylimidazole | 1 |
| 88 | canine-laypeople | 1 |
| 89 | isopimarane | 1 |
| 90 | sevoflurane/desflurane | 1 |
| 91 | tetra-cyano-ethyl-ene | 1 |
| 92 | n-phenylglycine | 1 |
| 93 | 2,3-aminopyridine | 1 |
| 94 | 3-spiro-2'-pyrrolidine-3'-spiro-3″-piperidine-2,3″-dione | 1 |
| 95 | 2,2,6,6-tetrametil-3,5-heptanodione | 1 |
| 96 | indoline-2-thione | 1 |
| 97 | 3,3'-dihydroxyflavone | 1 |
| 98 | ferredoxin-type | 1 |
| 99 | high-pressure/temperature | 1 |
| 100 | cocaine-opiate | 1 |
| 101 | acetyl-acetonate | 1 |
| 102 | pet-ct-positive | 1 |
| 103 | 39-h | 1 |
| 104 | 0000h-1200h | 1 |
| 105 | loh/msi | 1 |
| 106 | tablets/wk | 2 |
| 107 | frontomaxillo-facial | 1 |
| 108 | β-apo-8-carotenal | 1 |
| 109 | mid-pubertal | 1 |
| 110 | c57bl/6jjcl | 1 |
| 111 | 15μgl | 1 |
| 112 | non-white-blood-cell | 1 |
| 113 | 79.2-158.8microg/ml | 1 |
| 114 | 39-2500µg/ml | 1 |
| 115 | 19-625µg/ml | 1 |
| 116 | compounds-trans-phytol | 1 |
| 117 | uran-yl | 2 |
| 118 | 2p.m | 1 |
| 119 | 9:00am-10:00am | 1 |
| 120 | 190-200gm | 1 |
| 121 | 20-87microm | 1 |
| 122 | weeks=arm | 1 |
| 123 | midmyocardium/epicardium | 1 |
| 124 | midmyocardium/endocardium | 1 |
| 125 | monochromium | 1 |
| 126 | tetra-hydro-furan | 2 |
| 127 | neuroticismxextraversion | 1 |
| 128 | full-duration | 1 |
| 129 | htco | 1 |
| 130 | navo | 1 |
| 131 | cbp-hbp | 1 |
| 132 | hp-np | 1 |
| 133 | groups-group | 6 |
| 134 | 18/year | 1 |
| 135 | deltoid-intramuscular | 1 |
| 136 | deltamcr | 1 |
| 137 | regimens-zidovudine-lamivudine-abacavir | 1 |
| 138 | margin-pontic/connector | 1 |
| 139 | 1-1/bpvr | 1 |
| 140 | mnhsc70s | 1 |
| 141 | egas | 2 |
| 142 | angioectasias | 1 |
| 143 | hydrophobic-aromatics | 1 |
| 144 | gnathostomulids | 1 |
| 145 | ob-folds | 1 |
| 146 | edifices | 2 |
| 147 | hirsutinolides | 1 |
| 148 | monoglucuronides | 2 |
| 149 | flavanol-c-glucosides | 1 |
| 150 | subranges | 1 |
| 151 | strain-gauges | 1 |
| 152 | aproaches | 2 |
| 153 | sub-families | 2 |
| 154 | metaregistries | 1 |
| 155 | lithotrities | 1 |
| 156 | bisbenzimidazoles | 1 |
| 157 | regimens/schedules | 1 |
| 158 | half-cysteines | 1 |
| 159 | pain-types | 1 |
| 160 | daycares | 3 |
| 161 | isocentres | 4 |
| 162 | color-temperatures | 1 |
| 163 | citases | 2 |
| 164 | heat-presses | 2 |
| 165 | aspartates | 1 |
| 166 | meta-attributes | 2 |
| 167 | progressives | 6 |
| 168 | ag-complexes | 1 |
| 169 | poly-pom-mofs | 1 |
| 170 | aotfs | 1 |
| 171 | breast-feedings | 1 |
| 172 | pumpings | 2 |
| 173 | studies.meta-analysis | 1 |
| 174 | backpacks | 14 |
| 175 | test-meals | 3 |
| 176 | subtrials | 3 |
| 177 | sub-protocols | 1 |
| 178 | hydroxysterols | 1 |
| 179 | isoflavans | 1 |
| 180 | non-chloracnegens | 1 |
| 181 | b-strains | 1 |
| 182 | actins | 3 |
| 183 | declensions | 1 |
| 184 | treatment-sessions | 1 |
| 185 | non-fusions | 1 |
| 186 | ionizations | 1 |
| 187 | t-junctions | 1 |
| 188 | pianos | 1 |
| 189 | grupos | 1 |
| 190 | chirps | 1 |
| 191 | groups | 145,076 |
| 192 | feeding-groups | 1 |
| 193 | bmi-groups | 1 |
| 194 | treatment-groups | 3 |
| 195 | study-groups | 2 |
| 196 | twogroups | 2 |
| 197 | 70.0years | 1 |
| 198 | ≤30years | 2 |
| 199 | 61years | 1 |
| 200 | 25.5±5.2years | 1 |
| 201 | noncancers | 2 |
| 202 | wheelers | 1 |
| 203 | vass-users | 1 |
| 204 | gdt-parameters | 1 |
| 205 | capnometers | 2 |
| 206 | overs | 1 |
| 207 | groups-frs | 1 |
| 208 | tc-monitors | 1 |
| 209 | 59.1yrs | 1 |
| 210 | 44.8yrs | 1 |
| 211 | retreats | 1 |
| 212 | mediets | 2 |
| 213 | cpets | 1 |
| 214 | task-sets | 1 |
| 215 | ghsgts | 3 |
| 216 | dxa-results | 1 |
| 217 | weeks.results | 1 |
| 218 | alu-elements | 1 |
| 219 | cantonments | 1 |
| 220 | inquests | 1 |
| 221 | tsvs | 3 |
| 222 | groups/interviews | 2 |
| 223 | windrows | 5 |
| 224 | test-days | 3 |
| 225 | pdtp-dfbt | 2 |
| 226 | pre-spect | 1 |
| 227 | post-spect | 1 |
| 228 | pt-ht | 1 |
| 229 | clkt | 2 |
| 230 | 13w | 1 |
| 231 | anti-slex | 1 |
| 232 | x≤x | 1 |
| 233 | 55+y | 1 |
| 234 | 49y | 1 |
| 235 | cartridges/day | 1 |
| 236 | intraocularly/intranasally | 1 |
| 237 | years.adenoidectomy | 1 |
| 238 | tioblast™ | 1 |
| 239 | 55.9± | 1 |